| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.XPHS.2017.09.024 |
| P698 | PubMed publication ID | 28989014 |
| P2093 | author name string | George Zografi | |
| Susan M Reutzel-Edens | |||
| Ann Newman | |||
| P2860 | cites work | Relative bioavailability of three different solid forms of PNU-141659 as determined with the artificial stomach-duodenum model | Q84445202 |
| Analysis of Amorphous Solid Dispersions Using 2D Solid-State NMR and 1H T1 Relaxation Measurements | Q84646465 | ||
| Thermodynamics of Highly Supersaturated Aqueous Solutions of Poorly Water-Soluble Drugs-Impact of a Second Drug on the Solution Phase Behavior and Implications for Combination Products | Q85343539 | ||
| Early drug development predictions of glass-forming ability and physical stability of drugs | Q86542521 | ||
| Phase separation in coamorphous systems: in silico prediction and the experimental challenge of detection | Q87868764 | ||
| Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan | Q89131080 | ||
| Drug-Drug Multicomponent Solid Forms: Cocrystal, Coamorphous and Eutectic of Three Poorly Soluble Antihypertensive Drugs Using Mechanochemical Approach | Q89907610 | ||
| Data mining of solubility parameters for computational prediction of drug-excipient miscibility | Q30620456 | ||
| Characterization of cimetidine-piroxicam coprecipitate interaction using experimental studies and molecular dynamic simulations | Q33590757 | ||
| Long-Term Amorphous Drug Stability Predictions Using Easily Calculated, Predicted, and Measured Parameters | Q35734776 | ||
| New Perspectives for Fixed Dose Combinations of Poorly Water-Soluble Compounds: a Case Study with Ezetimibe and Lovastatin | Q35917803 | ||
| The Binary System of Ibuprofen-Nicotinamide Under Nanoscale Confinement: From Cocrystal to Coamorphous State. | Q36408457 | ||
| Study of the influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-L-lysine-cyclodextrin complexes | Q36854787 | ||
| Characterization of the "hygroscopic" properties of active pharmaceutical ingredients | Q36881364 | ||
| Pharmaceutical applications of hot-melt extrusion: Part II. | Q36982542 | ||
| Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview | Q37336809 | ||
| Water-solids interactions: deliquescence. | Q37963028 | ||
| Assessing the performance of amorphous solid dispersions | Q37972856 | ||
| Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties. | Q38161086 | ||
| Facts and fictions about polymorphism. | Q38591930 | ||
| Pharmaceutical cocrystals: along the path to improved medicines | Q38632654 | ||
| Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders | Q38665921 | ||
| Recent advances in co-amorphous drug formulations | Q38710042 | ||
| Rational excipient selection for co-amorphous formulations | Q38856865 | ||
| Stabilisation of an amorphous form of ROY through a predicted co-former interaction | Q38876711 | ||
| The Application of Modeling and Prediction to the Formation and Stability of Amorphous Solid Dispersions. | Q39227466 | ||
| A Model-Based Methodology for Spray-Drying Process Development | Q39578961 | ||
| Influence of variation in molar ratio on co-amorphous drug-amino acid systems | Q39638481 | ||
| Modeling Physical Stability of Amorphous Solids Based on Temperature and Moisture Stresses | Q39761686 | ||
| Preparation and recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin | Q39808123 | ||
| In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids | Q39934188 | ||
| Stable amorphous binary systems of glipizide and atorvastatin powders with enhanced dissolution profiles: formulation and characterization | Q40167348 | ||
| Co-Amorphous Combination of Nateglinide-Metformin Hydrochloride for Dissolution Enhancement. | Q40599950 | ||
| Simultaneous improvement of solubility and permeability by fabricating binary glassy materials of Talinolol with Naringin: Solid state characterization, in-vivo in-situ evaluation. | Q40647421 | ||
| Formation Mechanism of Coamorphous Drug-Amino Acid Mixtures. | Q40854029 | ||
| Evaluation of drug load and polymer by using a 96-well plate vacuum dry system for amorphous solid dispersion drug delivery | Q41988287 | ||
| Ternary systems of naproxen with hydroxypropyl-beta-cyclodextrin and aminoacids | Q42167986 | ||
| Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline | Q42936240 | ||
| A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion | Q42985877 | ||
| Small scale screening to determine the ability of different polymers to inhibit drug crystallization upon rapid solvent evaporation. | Q43035262 | ||
| Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation--classification and comparison with crystallization tendency from undercooled melts | Q43038522 | ||
| The roles of acidifiers in solid dispersions and physical mixtures | Q43270863 | ||
| Features of heat-induced amorphous complex between indomethacin and lidocaine. | Q44001187 | ||
| Eutectics as improved pharmaceutical materials: design, properties and characterization | Q44122680 | ||
| Water vapor absorption into amorphous hydrophobic drug/poly(vinylpyrrolidone) dispersions | Q44134189 | ||
| Coamorphous repaglinide-saccharin with enhanced dissolution | Q44516449 | ||
| Pairwise polymer blends for oral drug delivery | Q44998069 | ||
| Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process | Q45158430 | ||
| Solid-state characterization and dissolution properties of naproxen-arginine-hydroxypropyl-beta-cyclodextrin ternary system | Q45164882 | ||
| Cocrystallization and amorphization induced by drug-excipient interaction improves the physical properties of acyclovir. | Q45398135 | ||
| Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters | Q45729848 | ||
| Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement | Q45811011 | ||
| Rational coformer or solvent selection for pharmaceutical cocrystallization or desolvation | Q45823174 | ||
| Spray drying of budesonide, formoterol fumarate and their composites-II. Statistical factorial design and in vitro deposition properties | Q46311146 | ||
| Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions. | Q46318738 | ||
| Improved physical stability of amorphous state through acid base interactions | Q46330466 | ||
| A solid-state NMR study of phase structure, molecular interactions, and mobility in blends of citric acid and paracetamol | Q46358441 | ||
| Rheology and molecular mobility of amorphous blends of citric acid and paracetamol | Q46461847 | ||
| Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation | Q46471158 | ||
| Effect of counterions on the physical properties of l-arginine in frozen solutions and freeze-dried solids | Q46606637 | ||
| Characterization of amorphous API:Polymer mixtures using X-ray powder diffraction | Q46693297 | ||
| Co-amorphous Formation Induced by Combination of Tranilast and Diphenhydramine Hydrochloride | Q47397531 | ||
| Frozen in Time: Kinetically Stabilized Amorphous Solid Dispersions of Nifedipine Stable after a Quarter Century of Storage | Q48103006 | ||
| Computational Screening of Drug Solvates. | Q48137537 | ||
| Effect of Low-Concentration Polymers on Crystal Growth in Molecular Glasses: A Controlling Role for Polymer Segmental Mobility Relative to Host Dynamics. | Q48293538 | ||
| Molecular Dynamics and Physical Stability of Coamorphous Ezetimib and Indapamide Mixtures. | Q50247987 | ||
| Hot Melt Extrusion and Spray Drying of Co-amorphous Indomethacin-Arginine With Polymers | Q50277279 | ||
| A Strategy for Co-former Selection to Design Stable Co-amorphous Formations Based on Physicochemical Properties of Non-steroidal Inflammatory Drugs. | Q50898939 | ||
| Computational predictions of glass-forming ability and crystallization tendency of drug molecules. | Q51068397 | ||
| Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. | Q51169713 | ||
| pH-dependent solubility of indomethacin-saccharin and carbamazepine-saccharin cocrystals in aqueous media. | Q51336621 | ||
| Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen. | Q51542358 | ||
| Predicting the formation and stability of amorphous small molecule binary mixtures from computationally determined Flory-Huggins interaction parameter and phase diagram. | Q51709416 | ||
| A classification system to assess the crystallization tendency of organic molecules from undercooled melts. | Q52602052 | ||
| Drug-polymer interactions at water-crystal interfaces and implications for crystallization inhibition: molecular dynamics simulations of amphiphilic block copolymer interactions with tolazamide crystals. | Q53478806 | ||
| Computational approach for fast screening of small molecular candidates to inhibit crystallization in amorphous drugs. | Q53985901 | ||
| TowardIn SilicoPrediction of Glass-Forming Ability from Molecular Structure Alone: A Screening Tool in Early Drug Development | Q56487184 | ||
| Recent Advances in Understanding the Mechanism of Cocrystal Formation via Grinding | Q56769806 | ||
| Effect of Binary Additive Combinations on Solution Crystal Growth of the Poorly Water-Soluble Drug, Ritonavir | Q57346217 | ||
| Insights into Nano- and Micron-Scale Phase Separation in Amorphous Solid Dispersions Using Fluorescence-Based Techniques in Combination with Solid State Nuclear Magnetic Resonance Spectroscopy | Q57351454 | ||
| Inhibition of solution crystal growth of ritonavir by cellulose polymers – factors influencing polymer effectiveness | Q57376538 | ||
| Preparation and characterization of spray-dried co-amorphous drug-amino acid salts | Q59234161 | ||
| Properties of the Sodium Naproxen-Lactose-Tetrahydrate Co-Crystal upon Processing and Storage. | Q59234241 | ||
| Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin–arginine | Q59234265 | ||
| Amino Acids as Co-amorphous Excipients for Simvastatin and Glibenclamide: Physical Properties and Stability | Q59234361 | ||
| Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions | Q59234583 | ||
| Supramolecular Synthons in Crystal Engineering—A New Organic Synthesis | Q60176598 | ||
| Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures | Q72040505 | ||
| Non-isothermal and isothermal crystallization of sucrose from the amorphous state | Q72834299 | ||
| Effects of sorbed water on the crystallization of indomethacin from the amorphous state | Q73111164 | ||
| Solubility parameters as predictors of miscibility in solid dispersions | Q73188552 | ||
| Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization | Q73203971 | ||
| Properties of citric acid at the glass transition | Q74017388 | ||
| The effect of temperature on water vapor sorption by some amorphous pharmaceutical sugars | Q74458704 | ||
| Mixing behavior of colyophilized binary systems | Q74602172 | ||
| Characterisation of the glass transition of HPMC using modulated temperature differential scanning calorimetry | Q74629595 | ||
| Phase behavior of binary and ternary amorphous mixtures containing indomethacin, citric acid, and PVP | Q77097791 | ||
| A study of amorphous molecular dispersions of indomethacin and its sodium salt | Q77358554 | ||
| Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems | Q77412343 | ||
| Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions | Q80001519 | ||
| Cocrystal formation during cogrinding and storage is mediated by amorphous phase | Q80307600 | ||
| Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations | Q80368642 | ||
| Quantifying intermolecular interactions: guidelines for the molecular recognition toolbox | Q80828789 | ||
| Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable? | Q84240486 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bioavailability | Q461809 |
| P304 | page(s) | 5-17 | |
| P577 | publication date | 2017-10-05 | |
| P1433 | published in | Journal of Pharmaceutical Sciences | Q3186933 |
| P1476 | title | Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability | |
| P478 | volume | 107 |
| Q91603846 | Advances in coamorphous drug delivery systems |
| Q58586198 | An Examination of Water Vapor Sorption by Multi-Component Crystalline and Amorphous Solids and Its Effects on their Solid-State Properties |
| Q64902990 | Co-Amorphous Solid Dispersions for Solubility and Absorption Improvement of Drugs: Composition, Preparation, Characterization and Formulations for Oral Delivery. |
| Q89910002 | Co-amorphous solid dispersion systems of lacidipine-spironolactone with improved dissolution rate and enhanced physical stability |
| Q92062169 | Commentary: Considerations in the Measurement of Glass Transition Temperatures of Pharmaceutical Amorphous Solids |
| Q57174036 | Engineering Cocrystals of PoorlyWater-Soluble Drugs to Enhance Dissolution in Aqueous Medium |
| Q91855237 | Improving the Solubility, Dissolution, and Bioavailability of Ibrutinib by Preparing It in a Coamorphous State With Saccharin |
| Q64947964 | Polyelectrolytes in Hot Melt Extrusion: A Combined Solvent-Based and Interacting Additive Technique for Solid Dispersions. |
Search more.